Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1
International Journal of Molecular Sciences · 05.11.2025 · 26 (21) · 10755
DOI: 10.3390/ijms262110755 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.11.2025. Verfasst von Lily Darman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46617, USA. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Molecular Targeted Therapy, Isocitrate Dehydrogenase. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indiana University School of Medicine.
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is a biliary tract cancer that accounts for approximately 3% of all gastrointestinal cancers. CCA is a “silent” disease that remains undetected for a long period of time, often presenting at an advanced stage with minimal treatment options and a poor prognosis. Advanced CCA remains largely inoperable, and combination gemcitabine plus cisplatin (GemCis) chemotherapy remains the standard treatment for patients affected by this disease. There is a desperate need for new therapeutic alternatives, and extensive research is ongoing to address this gap. Targeted therapies represent a rapidly expanding area of cancer treatment and are currently under active investigation in CCA. The FDA has approved the targeted therapies ivosidenib, pemigatinib, infigratinib, and futibatinib, as well as the immunotherapy durvalumab, for patients with CCA in recent years. Several other therapeutic strategies are still under investigation, targeting molecular pathways including p53/MDM2, JAK/STAT, KRAS, HER2, VEGFR, PDGFR, MET, ALK, MAPK, PI3K/AKT, BRAF, and DNA damage repair signaling. While several promising advancements have been made, further research is required to improve outcomes for patients with CCA. This review provides an up-to-date, comprehensive overview of currently approved targeted therapies in CCA, as well as those under investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46617, USA.
- Department of Surgery, Indiana University School of Medicine, South Bend, IN 46617, USA.
- Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46617, USA.
- Goshen Center for Cancer Care, Goshen, IN 46526, USA.
- School of Medicine, University of Basel, CH-4056 Basel, Switzerland.
ORCID-Profile: Quinn Kaurich, Md Sazzad Hassan
Förderung
- Indiana University School of Medicine
Zitieren
APA
Darman, L., Kaurich, Q., Hassan, M. S., von Holzen, U., & Awasthi, N. (2025). Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1. International Journal of Molecular Sciences, 26(21), 10755. https://doi.org/10.3390/ijms262110755
Vancouver
Darman L, Kaurich Q, Hassan MS, von Holzen U, Awasthi N. Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1. International Journal of Molecular Sciences. 2025;26(21):10755. doi:10.3390/ijms262110755
BibTeX
@article{Darman2025,
author = {Darman, Lily and Kaurich, Quinn and Hassan, Md Sazzad and von Holzen, Urs and Awasthi, Niranjan},
title = {Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {21},
pages = {10755},
doi = {10.3390/ijms262110755}
}
EUVIMED